Finland· FI-REL-REL64045
Rybrevant
A amivantamab product containing amivantamab, registered in Finland by Janssen-Cilag International NV. The same ATC class is registered in 15 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Amivantamab is registered in 15 of 19 countries.
Countries holding a registration under ATC L01FX18 (amivantamab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Amivantamab · ATC L01FX18
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of amivantamab costs, country by country.
Normalised to the WHO defined daily dose (75 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Amivantamab · price per daily dose (75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$335.64
The record
At a glance
Fimea (Finland)- Active substance
- Amivantamab
- Manufacturer
- Janssen-Cilag International NV
- Country
- Finland (FI)
- ATC code
- L01FX18
- ATC class
- Amivantamab
- Defined daily dose
- 75 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Amivantamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumRybrevant 1600 mgJanssen-Cilag International
- NorwayRybrevantJanssen-Cilag International N.V.
- NetherlandsRybrevant 1600 mg, oplossing voor injectieJanssen-Cilag International NV
- CzechiaRYBREVANTJanssen-Cilag International N.V., Beerse
- SpainRYBREVANT 1600 MG SOLUCION INYECTABLEJanssen-Cilag International N.V
- IcelandRybrevantJanssen-Cilag International NV*
- PolandRybrevantJanssen-Cilag International N.V.
- SwedenRybrevant 1600 mg Injektionsvätska, lösningJanssen-Cilag International NV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rybrevant
- Liechtenstein · Rybrevant
- Norway · Rybrevant
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2c9e13c2-30cb-4435-bdae-a66b2d94c20f GET /v1/drugs/2c9e13c2-30cb-4435-bdae-a66b2d94c20f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektioneste, liuos",
"route": "Ihon alle",
"ddd_unit": null,
"strength": "2240 mg",
"atc_label": "amivantamabi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/21/1594/003",
"fimea_rel_id": "REL64045",
"authorised_at": "2025-04-04"
}See everything about amivantamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.